Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration

BACKGROUND: Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). Systemic use of bevacizumab has been linked to a wide range of renal adverse effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Khneizer, Gebran, Al-Taee, Ahmad, Bastani, Bahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Diabetic Nephropathy Prevention 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607973/
https://www.ncbi.nlm.nih.gov/pubmed/28975092
http://dx.doi.org/10.15171/jnp.2017.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607973/
https://www.ncbi.nlm.nih.gov/pubmed/28975092
http://dx.doi.org/10.15171/jnp.2017.23

Ejemplares similares